Aristotle Capital Management LLC purchased a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 175,757 shares of the specialty pharmaceutical company’s stock, valued at approximately $22,748,000. Aristotle Capital […]
Rhenman & Partners Asset Management AB decreased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 0.9% in the 3rd quarter, HoldingsChannel reports. The firm owned 143,634 shares of the specialty pharmaceutical company’s stock after selling 1,366 shares during the quarter. Jazz Pharmaceuticals makes up 2.0% of Rhenman & Partners Asset Management AB’s […]
Barclays PLC increased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 9.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 99,366 shares of the specialty pharmaceutical company’s stock after purchasing an additional 8,834 shares during the […]
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) had its price objective dropped by Barclays from $240.00 to $235.00 in a research report issued on Monday, Benzinga reports. The firm currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Barclays‘s price target would suggest a potential upside of 87.16% from the company’s previous close. […]
Retirement Systems of Alabama reduced its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 2.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 172,931 shares of the specialty pharmaceutical company’s stock after selling 3,651 shares during the quarter. Retirement […]